Key terms
About ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ZYME news
Apr 12
6:27am ET
Maintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory Hurdles
Apr 08
7:07am ET
Zymeworks Unveils Promising Cancer Research
Apr 04
6:13am ET
Zymeworks CFO Dr. Astle Exits with Severance Package
Apr 01
9:12am ET
Zymeworks Announces Executive Shake-Up, Appoints Interim CFO
Mar 28
4:33pm ET
Zymeworks Inc. Strengthens Board with Dr. Gallagher’s Appointment
Mar 28
6:37am ET
Zymeworks Bolsters Board with Oncology Expert
Mar 13
10:00am ET
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Mar 12
6:25am ET
Zymeworks price target raised to $14 from $12 at Wells Fargo
Mar 12
5:16am ET
Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab
Mar 11
10:05pm ET
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Mar 11
6:12am ET
Zymeworks price target raised to $10 from $8 at H.C. Wainwright
Mar 11
12:46am ET
Hold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation Awaited
Mar 08
1:01am ET
Zymeworks’ New Costs Risk – A Cause for Worry?
Mar 07
4:48pm ET
Zymeworks files to sell 5.09M shares of common stock for holders
Mar 07
11:32am ET
Zymeworks price target raised to $21 from $19 at Stifel
Mar 06
5:27pm ET
Zymeworks files to sell 5.09M shares of common stock for holders
Mar 06
5:08pm ET
Zymeworks Poised for Growth with Strong Cash Position
Mar 06
4:31pm ET
Zymeworks reports Q4 adjusted EPS (16c), consensus (43c)
Mar 05
5:07pm ET
Zymeworks Highlights Cancer Therapeutics at AACR
Feb 27
6:37am ET
Zymeworks to Present at Upcoming Health Conferences
Feb 22
4:40pm ET
Zymeworks Inc. Bolsters Board with Strategic New Director
Feb 09
4:52am ET
Zymeworks Inc Enhances Leadership and Governance Structure
Feb 09
4:52am ET
Zymeworks Inc Announces Board Appointments and Resignation
Jan 25
7:14am ET
Zentalis appoints Hausman as CMO, Rasbach as CBO
Today
7:30am ET
ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.
Apr 16
4:15pm ET
Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud Allegations
Apr 14
4:16pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
Apr 12
10:05am ET
Zymeworks Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zymeworks (ZYME)
Apr 12
10:00am ET
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
Apr 12
7:30am ET
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ZYME
Apr 10
4:45pm ET
Did Zymeworks Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZYME
Apr 08
4:00pm ET
Zymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ZYME
Apr 06
1:18pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
ZYME Financials
Key terms
Ad Feedback
ZYME Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ZYME Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
